We examine the transformative potential of artificial intelligence (AI) in medical imaging diagnosis, focusing on improving diagnostic accuracy and efficiency through advanced algorithms. It addresses the significant challenges preventing immediate clinical adoption of AI, specifically from technical, ethical, and legal perspectives. The aim is to highlight the current state of AI in medical imaging and outline the necessary steps to ensure safe, effective, and ethically sound clinical implementation. We conduct a comprehensive discussion, with special emphasis on the technical requirements for robust AI models, the ethical frameworks needed for responsible deployment, and the legal implications, including data privacy and regulatory compliance. Explainable artificial intelligence (XAI) is examined as a means to increase transparency and build trust among healthcare professionals and patients. The analysis reveals key challenges to AI integration in clinical settings, including the need for extensive high-quality datasets, model reliability, advanced infrastructure, and compliance with regulatory standards. The lack of explainability in AI outputs remains a barrier, with XAI identified as crucial for meeting transparency standards and enhancing trust among end users. Overcoming these barriers requires a collaborative, multidisciplinary approach to integrate AI into clinical practice responsibly. Addressing technical, ethical, and legal issues will support a softer transition, fostering a more accurate, efficient, and patient-centered healthcare system where AI augments traditional medical practices.

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States, largely due to its poor five-year survival rate and frequent late-stage diagnosis. A significant barrier to early detection even in high-risk cohorts is that the pancreas often appears morphologically normal during the pre-diagnostic phase. Yet, the disease can progress rapidly from subclinical stages to widespread metastasis, undermining the effectiveness of screening. Recently, artificial intelligence (AI) applied to cross-sectional imaging has shown significant potential in identifying subtle, early-stage changes in pancreatic tissue that are often imperceptible to the human eye. Moreover, AI-driven imaging also aids in the discovery of prognostic and predictive biomarkers, essential for personalized treatment planning. This article uniquely integrates a critical discussion on AI's role in detecting visually occult PDAC on pre-diagnostic imaging, addresses challenges of model generalizability, and emphasizes solutions like standardized datasets and clinical workflows. By focusing on both technical advancements and practical implementation, this article provides a forward-thinking conceptual framework that bridges current gaps in AI-driven PDAC research.

This bibliometric analysis aims to explore scientific data on Artificial Intelligence (AI) and Head and Neck Cancer (HNC). AI-related HNC articles from the Web of Science Core Collection were searched. VosViewer and Biblioshiny/Bibiometrix for R Studio were used for data synthesis. This analysis covered key characteristics such as sources, authors, affiliations, countries, citations and top cited articles, keyword analysis, and trending topics. A total of 1,019 papers from 1995 to 2024 were included. Among them, 71.6% were original research articles, 7.6% were reviews, and 20.8% took other forms. The fifty most cited documents highlighted radiology as the most explored specialty, with an emphasis on deep learning models for segmentation. The publications have been increasing, with an annual growth rate of 94.4% after 2016. Among the 20 most productive countries, 14 are high-income economies. The keywords of strong citation revealed 2 main clusters: radiomics and radiotherapy. The most frequently keywords include machine learning, deep learning, artificial intelligence, and head and neck cancer, with recent emphasis on diagnosis, survival prediction, and histopathology. There has been an increase in the use of AI in HNC research since 2016 and indicated a notable disparity in publication quantity between high-income and low/middle-income countries. Future research should prioritize clinical validation and standardization to facilitate the integration of AI in HNC management, particularly in underrepresented regions.

This article explores the transformative potential of artificial intelligence (AI) in critical care ultrasound AI technologies, notably deep learning and convolutional neural networks, now assisting in image acquisition, interpretation, and quality assessment, streamlining workflow and reducing operator variability. By automating routine tasks, AI enhances diagnostic accuracy and bridges training gaps, potentially democratizing advanced ultrasound techniques. Furthermore, AI's integration into tele-ultrasound systems shows promise in extending expert-level diagnostics to underserved areas, significantly broadening access to quality care. The article highlights the ongoing need for explainable AI systems to gain clinician trust and facilitate broader adoption.

Coronary CT Angiography (CCTA) is essential for assessing atherosclerosis and coronary artery disease, aiding in early detection, risk prediction, and clinical assessment. However, traditional CCTA interpretation is limited by observer variability, time inefficiency, and inconsistent plaque characterization. AI has emerged as a transformative tool, enhancing diagnostic accuracy, workflow efficiency, and risk prediction for major adverse cardiovascular events (MACE). Studies show that AI improves stenosis detection by 27%, inter-reader agreement by 30%, and reduces reporting times by 40%, thereby addressing key limitations of manual interpretation. Integrating AI with multimodal imaging (e.g., FFR-CT, PET-CT) further enhances ischemia detection by 28% and lesion classification by 35%, providing a more comprehensive cardiovascular evaluation. This review synthesizes recent advancements in CCTA-AI automation, risk stratification, and precision diagnostics while critically analyzing data quality, generalizability, ethics, and regulation challenges. Future directions, including real-time AI-assisted triage, cloud-based diagnostics, and AI-driven personalized medicine, are explored for their potential to revolutionize clinical workflows and optimize patient outcomes.

Radiology has evolved from the pioneering days of X-ray imaging to a field rich in advanced technologies on the cusp of a transformative future driven by artificial intelligence (AI). As imaging workloads grow in volume and complexity, and economic as well as environmental pressures intensify, visionary leadership is needed to navigate the unprecedented challenges and opportunities ahead. Leveraging its strengths in automation, accuracy and objectivity, AI will profoundly impact all aspects of radiology practice-from workflow management, to imaging, diagnostics, reporting and data-driven analytics-freeing radiologists to focus on value-driven tasks that improve patient care. However, successful AI integration requires strong leadership and robust governance structures to oversee algorithm evaluation, deployment, and ongoing maintenance, steering the transition from static to continuous learning systems. The vision of a "diagnostic cockpit" that integrates multidimensional data for quantitative precision diagnoses depends on visionary leadership that fosters innovation and interdisciplinary collaboration. Through administrative automation, precision medicine, and predictive analytics, AI can enhance operational efficiency, reduce administrative burden, and optimize resource allocation, leading to substantial cost reductions. Leaders need to understand not only the technical aspects but also the complex human, administrative, and organizational challenges of AI's implementation. Establishing sound governance and organizational frameworks will be essential to ensure ethical compliance and appropriate oversight of AI algorithms. As radiology advances toward this AI-driven future, leaders must cultivate an environment where technology enhances rather than replaces human skills, upholding an unwavering commitment to human-centered care. Their vision will define radiology's pioneering role in AI-enabled healthcare transformation. KEY POINTS: Question Artificial intelligence (AI) will transform radiology, improving workflow efficiency, reducing administrative burden, and optimizing resource allocation to meet imaging workloads' increasing complexity and volume. Findings Strong leadership and governance ensure ethical deployment of AI, steering the transition from static to continuous learning systems while fostering interdisciplinary innovation and collaboration. Clinical relevance Visionary leaders must harness AI to enhance, rather than replace, the role of professionals in radiology, advancing human-centered care while pioneering healthcare transformation.

Clinical decision-making is inherently complex, time-sensitive, and prone to error. AI-enabled clinical decision support systems (CDSS) offer promising solutions by leveraging large datasets to provide evidence-based recommendations. These systems range from rule-based and knowledge-based to increasingly AI-driven approaches. However, key challenges persist, particularly concerning data quality, seamless integration into clinical workflows, and clinician trust and acceptance. Ethical and legal considerations, especially data privacy, are also paramount.AI-CDSS have demonstrated success in fields like radiology (e.g., pulmonary nodule detection, mammography interpretation) and cardiology, where they enhance diagnostic accuracy and improve patient outcomes. Looking ahead, chat and voice interfaces powered by large language models (LLMs) could support shared decision-making (SDM) by fostering better patient engagement and understanding.To fully realize the potential of AI-CDSS in advancing efficient, patient-centered care, it is essential to ensure their responsible development. This includes grounding AI models in domain-specific data, anonymizing user inputs, and implementing rigorous validation of AI-generated outputs before presentation. Thoughtful design and ethical oversight will be critical to integrating AI safely and effectively into clinical practice.

As artificial intelligence (AI) becomes increasingly prevalent within interventional radiology (IR) research and clinical practice, steps must be taken to ensure the robustness of novel technological systems presented in peer-reviewed journals. This report introduces comprehensive standards and an evaluation checklist (iCARE) that covers the application of modern AI methods in IR-specific contexts. The iCARE checklist encompasses the full "code-to-clinic" pipeline of AI development, including dataset curation, pre-training, task-specific training, explainability, privacy protection, bias mitigation, reproducibility, and model deployment. The iCARE checklist aims to support the development of safe, generalizable technologies for enhancing IR workflows, the delivery of care, and patient outcomes.

Pathological complete response (pCR) to neoadjuvant systemic therapy (NAST) is an established prognostic marker in breast cancer (BC). Multimodal deep learning (DL), integrating diverse data sources (radiology, pathology, omics, clinical), holds promise for improving pCR prediction accuracy. This systematic review synthesizes evidence on multimodal DL for pCR prediction and compares its performance against unimodal DL. Following PRISMA, we searched PubMed, Embase, and Web of Science (January 2015-April 2025) for studies applying DL to predict pCR in BC patients receiving NAST, using data from radiology, digital pathology (DP), multi-omics, and/or clinical records, and reporting AUC. Data on study design, DL architectures, and performance (AUC) were extracted. A narrative synthesis was conducted due to heterogeneity. Fifty-one studies, mostly retrospective (90.2%, median cohort 281), were included. Magnetic resonance imaging and DP were common primary modalities. Multimodal approaches were used in 52.9% of studies, often combining imaging with clinical data. Convolutional neural networks were the dominant architecture (88.2%). Longitudinal imaging improved prediction over baseline-only (median AUC 0.91 vs. 0.82). Overall, the median AUC across studies was 0.88, with 35.3% achieving AUC ≥ 0.90. Multimodal models showed a modest but consistent improvement over unimodal approaches (median AUC 0.88 vs. 0.83). Omics and clinical text were rarely primary DL inputs. DL models demonstrate promising accuracy for pCR prediction, especially when integrating multiple modalities and longitudinal imaging. However, significant methodological heterogeneity, reliance on retrospective data, and limited external validation hinder clinical translation. Future research should prioritize prospective validation, integration underutilized data (multi-omics, clinical), and explainable AI to advance DL predictors to the clinical setting.